Anne Knisely, MD, MPH
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
Education & Training
Degree-Granting Education
| 2024 | University of Texas School of Public Health, US, Master of Public Health |
| 2018 | University of Virginia School of Medicine, US, Doctor of Medicine |
| 2014 | Unviersity of Virgina, Bachelor of Science in Biochemistry, with Distinction |
Postgraduate Training
| 2022-2026 | Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2018-2022 | Residency, Obstetrics & Gynecology, New York Presbyterian Hospital, New York |
Experience & Service
Other Professional Positions
Fellowship Admissions Committee, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - 2026
Research Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - 2024
Coordinator, Columbia University Medical Center, New York, New York, 2019 - 2021
Class Representative, University of Virginia School of Medicine, 2018 - Present
Co-Founder, University of Virginia School of Medicine, 2016 - 2018
Administrative Chief Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2015 - 2016
Teaching Assistant, University of Virginia, Charlottesville, Virginia, 2011 - 2014
Honors & Awards
| 2023 | Linda Manning Fellowship in Ovarian Cancer Research Award |
| 2023 | TRANSCEND Cancer Initiative Symposium, The University of Texas MD Anderson Cancer Center |
| 2022 | The Howard C. Taylor Award for Excellence in Teaching |
| 2022 | Outstanding Resident in Gynecologic Oncology |
| 2021 | Award for Excellence in Female Pelvic Medicine and Reconstructive Surgery |
| 2020 | Brunschwig Rotating Resident, Memorial Sloan Kettering Cancer Center |
| 2020 | Medical Student Excellence in Teaching Award |
| 2019 | Resident of the Month, The Allen Hosptial |
| 2014 | Robert Burnett Undergraduate Teaching Award |
| 2014 | Oscar R. Rodig Alpha Chi Sigma Chemistry Award |
| 2013 | The Rockefeller University Summer Undergraduate Research Fellowship |
| 2013 | The Rockefeller University Summer Undergraduate Research Fellowship |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2025. Inactivating PPP2R1A mutations are associated with prolonged survival after lenvatinib and pembrolizumab treatment in recurrent, microsatellite stable endometrial cancer. Panelist. Winter SGO Annual Meeting, US.
- 2024. Longitudinal spatial profiling reveals chemoresistance mechanisms and characteristics of minimal residual disease in high-grade serous ovarian cancer. Poster. AACR Annual Meeting. San Diego, California, US.
- 2024. Prognostic implications of minimal residual disease detection by second look laparoscopy and circulating tumor DNA in patients with ovarian cancer after frontline therapy. Panelist. SGO Annual Meeting on Women's Cancer. San Diego, California, US.
- 2024. A new standard for surgical site infection prevention in gynecologic cancer: Metronidazole plus cefazolin better than cefazolin alone. Poster. SGO Annual Meeting. San Diego, California, US.
- 2024. Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare. Poster. SGO Annual Meeting. San Diego, California, US.
- 2024. Intraperitoneal administration of dual immune checkpoint inhibitor therapy in recurrent gynecologic malignancies: Updated results of a phase 1b study. Panelist. Winter SGO Annual Meeting. Olympic Valley, California, US.
- 2023. Pilot studies of ovarian cancer minimal residual disease. Panelist. Break Through Cancer Summit. Kiawah Island, South Carolina, US.
- 2023. Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies. Poster. SITC Annual Meeting. San Diego, California, US.
International Presentations
- 2024. Minimal residual disease as a prognostic marker and opportunity for intervention in advanced ovarian cancer. Poster.
- 2024. Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer. Poster. ASCO Annual Meeting.
Selected Publications
Peer-Reviewed Articles
- Knisely A, Dai Y, Barlow GL, Lee S, Lawson B, Clark H, Fellman B, Yuan Y, Lu W, Lubo Julio IC, Lazcano RN, Chelvanambi M, Melendez B, Singh B, Singh B, Wani K, Chen J, Yeh CC, Gao J, Barnes S, Shi O, Khan KB, Serrano AG, Gomez-Bolanos LI, Scalise CB, Cheung SK, Dutta P, Velichko S, ElNaggar AC, Liu MC, Wilke RN, How J, Ramondetta LM, Boruta DM, Richardson G, Shafer A, Westin SN, Sims T, Sood AK, Ramirez PT, Lazar AJ, Soliman PT, Lu K, Haymaker CL, Solis Soto LM, Wargo JA, Grisham R, Wucherpfennig KW, Wang L, Jazaeri AA. Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities. Clin Cancer Res 31(19):4122-4135, 2025. e-Pub 2025. PMID: 40748258.
- Ahmed J, Knisely A, Torrado C, Stephen B, Yang Y, Song J, Alshawa A, Zarifa A, Jhingran A, Koay EJ, Morris VK, Javle M, Wolff RA, Meric-Bernstam F, Pant S, Rodon J, Naing A. A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies. Oncologist 30(3), 2025. e-Pub 2025. PMID: 40139261.
- Knisely A, Wu CF, Kanbergs A, Agusti N, Jorgensen KA, Melamed A, Giordano SH, Rauh-Hain JA, Nitecki Wilke R. Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare. Int J Gynecol Cancer 34(11):1661-1670, 2024. e-Pub 2024. PMID: 39084695.
- Knisely A, Iniesta MD, Marten CA, Chisholm G, Schmeler KM, Taylor JS. Metronidazole and cefazolin vs cefazolin alone for surgical site infection prophylaxis in gynecologic surgery at a comprehensive cancer center. Am J Obstet Gynecol 231(3):326.e1-326.e13, 2024. e-Pub 2024. PMID: 38599478.
- Knisely A, Hinchcliff EM, Gardiner E, Rangwala R, Lito K, Fellman B, Yuan Y, Sood AK, Westin SN, Lu KH, Jazaeri AA. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. iScience 27(5):109801, 2024. e-Pub 2024. PMID: 38726365.
- Knisely A, Hinchcliff E, Fellman B, Mosley A, Lito K, Hull S, Westin SN, Sood AK, Schmeler KM, Taylor JS, Huang SY, Sheth RA, Lu KH, Jazaeri AA. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med 5(4):311-320.e3, 2024. e-Pub 2024. PMID: 38471508.
- Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer 130(7):1061-1071, 2024. e-Pub 2024. PMID: 38009662.
- Knisely A, Iniesta MD, Batman S, Meyer LA, Soliman PT, Cain KE, Marten C, Chisholm G, Schmeler KM, Taylor JS, Fleming ND. Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center. Gynecol Oncol 183:120-125, 2024. e-Pub 2024. PMID: 38368180.
- Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer 12(2), 2024. e-Pub 2024. PMID: 38309721.
- Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130(3):400-409, 2024. e-Pub 2024. PMID: 37864520.
- Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, Lawson BC, Burns KH, Lee S, Westin SN, Moiso E, Williams MJ, Bardhan NM, Pisanic T, Matulonis U, Weigelt B, Shih I, Konstantinopoulos PA, Gaillard S, Wang L, Aghajanian C, D'Andrea AD, Hammond P, Shah S, Wucherpfennig KW, Lu KH. Transforming ovarian cancer care by targeting minimal residual disease. Med 4(11):755-760, 2023. e-Pub 2023. PMID: 37951209.
- Knisely A, Huang Y, Li Y, Prabhu VS, Wright JD. Adjuvant and first line chemotherapy use for endometrial cancer. Gynecol Oncol Rep 41:101002, 2022. e-Pub 2022. PMID: 35620299.
- Lara OD, Smith M, Wang Y, O'Cearbhaill RE, Blank SV, Kolev V, Carr C, Knisely A, McEachron J, Gabor L, Chapman-Davis E, Cohen S, Fehniger J, Lee YC, Isani S, Liu M, Wright JD, Pothuri B. COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic. Gynecol Oncol 164(2):304-310, 2022. e-Pub 2022. PMID: 34922769.
- Knisely A, Huang Y, Melamed A, Gockley A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Accordino M, Hershman DL, Wright JD. Disparities in Access to High-Volume Surgeons Within High-Volume Hospitals for Hysterectomy. Obstet Gynecol 138(2):208-217, 2021. e-Pub 2021. PMID: 34237769.
- Lara OD, Smith MJ, Wang Y, O'Cearbhaill R, Blank SV, Kolev V, Carr C, Knisely A, McEachron J, Gabor L, Chapman-Davis E, Jee J, Fehniger J, Lee YC, Isani S, Liu M, Wright JD, Pothuri B. Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancy. Cancer 127(7):1057-1067, 2021. e-Pub 2021. PMID: 33294978.
- Knisely A, Zhou ZN, Wu J, Huang Y, Holcomb K, Melamed A, Advincula AP, Lalwani A, Khoury-Collado F, Tergas AI, St Clair CM, Hou JY, Hershman DL, D'Alton ME, Huang YY, Wright JD. Perioperative Morbidity and Mortality of Patients With COVID-19 Who Undergo Urgent and Emergent Surgical Procedures. Ann Surg 273(1):34-40, 2021. e-Pub 2021. PMID: 33074900.
- Smith M, Lara OD, O'Cearbhaill R, Knisely A, McEachron J, Gabor L, Carr C, Blank S, Prasad-Hayes M, Frey M, Jee J, Fehniger J, Wang Y, Lee YC, Isani S, Wright JD, Pothuri B. Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection. Gynecol Oncol 159(3):618-622, 2020. e-Pub 2020. PMID: 33019984.
- Lara OD, O'Cearbhaill RE, Smith MJ, Sutter ME, Knisely A, McEachron J, Gabor LR, Jee J, Fehniger JE, Lee YC, Isani SS, Wright JD, Pothuri B. COVID-19 outcomes of patients with gynecologic cancer in New York City. Cancer 126(19):4294-4303, 2020. e-Pub 2020. PMID: 32729142.
- Knisely A, Wu J, Kaplan SJ, Zhou ZN, Melamed A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Huang YY, Hershman DL, Wright JD. Coronavirus Spectrum Infections (COVID-19, MERS, SARS) in Cancer Patients: A Systematic Review of the Literature. Cancer Invest 38(8-9):436-444, 2020. e-Pub 2020. PMID: 32787597.
- Knisely AT, St Clair CM, Hou JY, Collado FK, Hershman DL, Wright JD, Melamed A. Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016. SGO Annual Meeting 3(9):e2017517, 2020. e-Pub 2020. PMID: 32975569.
- Knisely AT, Stewart ME, Garcia C, Thomas MH, Modesitt SC, Ring KL. Evaluation of breast screening strategies in a high risk breast and ovarian cancer clinic. Gynecol Oncol Rep 33:100587, 2020. e-Pub 2020. PMID: 32490124.
- Knisely A, Huang Y, Melamed A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Neugut AI, Hershman DL, Wright JD. Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes. Gynecol Oncol 158(2):415-423, 2020. e-Pub 2020. PMID: 32456990.
- Hassinger TE, Berger AC, Christopher A, Knisely AT, Mehaffey JH, Brenin DR, Schroen AT, Showalter SL. Diabetes Mellitus and Metformin Are Not Associated With Breast Cancer Pathologic Complete Response. J Surg Res 247:52-58, 2020. e-Pub 2020. PMID: 31787317.
- Knisely A, Huang Y, Melamed A, Tergas AI, St Clair CM, Hou JY, Khoury-Collado F, Ananth CV, Neugut AI, Hershman DL, Wright JD. Effect of regionalization of endometrial cancer care on site of care and patient travel. Am J Obstet Gynecol 222(1):58.e1-58.e10, 2020. e-Pub 2020. PMID: 31344350.
- Hassinger TE, Mehaffey JH, Knisely AT, Contrella BN, Brenin DR, Schroen AT, Schirmer BD, Hallowell PT, Harvey JA, Showalter SL. The impact of bariatric surgery on qualitative and quantitative breast density. Breast J 25(6):1198-1205, 2019. e-Pub 2019. PMID: 31310402.
- Stewart ME, Knisely AT, Sullivan MW, Ring KL, Modesitt SC. Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers. ACOG Annual Clinical and Scientific Meeting 28:18-22, 2019. e-Pub 2019. PMID: 30775416.
- Knisely AT, Michaels AD, Mehaffey JH, Hassinger TE, Krebs ED, Brenin DR, Schroen AT, Showalter SL. Race is associated with completion of neoadjuvant chemotherapy for breast cancer. Surgery 164(2):195-200, 2018. e-Pub 2018. PMID: 29731247.
- Knisely AT, Girton MR, Hintz HC, Modesitt SC. Vaginal sarcoidosis without other organ involvement in a patient with a history of endometrial cancer: A case report. Gynecol Oncol Rep 23:34-36, 2018. e-Pub 2018. PMID: 29892684.
- Naik BI, Tsang S, Knisely A, Yerra S, Durieux ME. Retrospective case-control non-inferiority analysis of intravenous lidocaine in a colorectal surgery enhanced recovery program. BMC Anesthesiol 17(1):16, 2017. e-Pub 2017. PMID: 28143397.
- Naik BI, Durieux ME, Knisely A, Sharma J, Bui-Huynh VC, Yalamuru B, Terkawi AS, Nemergut EC. SEER Sonorheometry Versus Rotational Thromboelastometry in Large Volume Blood Loss Spine Surgery. Anesth Analg 123(6):1380-1389, 2016. e-Pub 2016. PMID: 27584686.
Review Articles
- Knisely A, Seo YD, Wargo JA, Chelvanambi M. Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment. Cancers (Basel) 15(3), 2023. e-Pub 2023. PMID: 36765735.
Other Articles
- Dai Y, Knisely A, Yano M, Dang M, Hinchcliff EM, Lee S, Welp A, Chelvanambi M, Lastrapes M, Liu H, Yuan Z, Wang C, Nie H, Jean S, Montaner LJ, Hou J, Patel A, Patel S, Fellman B, Yuan Y, Sun B, Pandurengan RK, Cuentas ERP, Celestino J, Liu Y, Liu J, Hillman RT, Westin SN, Sood AK, Soliman PT, Shafer A, Meyer LA, Gershenson DM, Vining D, Ganeshan D, Lu K, Wargo JA, Peng W, Zhang R, Wang L, Jazaeri AA PPP2R1A mutations portend improved survival after cancer immunotherapy. Nature 645(8082):E10, 2025. PMID: 40604275.
- Knisely A, Gamble CR, St Clair CM, Hou JY, Khoury-Collado F, Gockley AA, Wright JD, Melamed A The Role of Minimally Invasive Surgery in the Care of Women with Ovarian Cancer: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol 28(3):537-543, 2021. PMID: 33202311.
Editorials
- Knisely A, Fleming ND. The Use of Apixaban for Postoperative Venous Thromboembolism Prophylaxis in Gynecologic Cancer. Ann Surg Oncol 31(8):4855-4857, 2024. PMID: 38836916.
Book Chapters
- Knisely A, Wright JD. Diagnosis and Treatment of Rare Gynecologic Cancers, 2022.
Patient Reviews
CV information above last modified August 04, 2026